Weekly Investment Analysts’ Ratings Updates for Erasca (ERAS)

A number of firms have modified their ratings and price targets on shares of Erasca (NASDAQ: ERAS) recently:

• 7/14/2026 – Erasca had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 7/14/2026 – Erasca was given a new $24.00 price target by Jefferies Financial Group Inc..
• 7/14/2026 – Erasca was given a new $20.00 price target by HSBC Holdings plc.
• 7/14/2026 – Erasca had its “buy” rating reaffirmed by HC Wainwright.
• 7/14/2026 – Erasca had its price target raised by Bank of America Corporation from $16.00 to $18.00. They now have a “neutral” rating on the stock.
• 6/11/2026 – Erasca had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/4/2026 – Erasca was given a new $16.00 price target by Wolfe Research.
• 6/4/2026 – Erasca was upgraded by Bank of America Corporation from “underperform” to “neutral”. They now have a $16.00 price target on the stock, up from $9.00.
• 5/16/2026 – Erasca was downgraded by Wall Street Zen from “hold” to “sell”.

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.